EirGenix Inc. (TPEX:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.20
-0.10 (-0.12%)
Feb 21, 2025, 1:30 PM CST
-14.53%
Market Cap 24.87B
Revenue (ttm) 1.17B
Net Income (ttm) -986.69M
Shares Out 306.25M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 285,342
Average Volume 619,521
Open 81.90
Previous Close 81.30
Day's Range 80.50 - 81.90
52-Week Range 66.90 - 100.50
Beta 0.62
RSI 52.83
Earnings Date Mar 21, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2023, EirGenix's revenue was 1.02 billion, a decrease of -30.95% compared to the previous year's 1.48 billion. Losses were -915.21 million, 692.1% more than in 2022.

Financial Statements

News

There is no news available yet.